Flagship Pioneering And Pfizer Have Partnered To Create A New Pipeline Of Innovative Medicines, Wherein Flagship And Pfizer Will Each Invest $50M Upfront To Explore Opportunities To Develop 10 Single-asset Programs
Portfolio Pulse from Benzinga Newsdesk
Flagship Pioneering and Pfizer have partnered to create a new pipeline of innovative medicines. Both companies will invest $50M upfront to develop 10 single-asset programs. Pfizer will fund and have an option to acquire each selected development program. Flagship and its bioplatform companies could receive up to $700M in milestones and royalties for each successfully commercialized program.
July 18, 2023 | 11:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer's partnership with Flagship Pioneering could lead to the development of new medicines, with Pfizer having the option to acquire each program. This could potentially increase Pfizer's product portfolio and future revenue streams.
The partnership with Flagship Pioneering allows Pfizer to potentially expand its product portfolio by acquiring new development programs. This could lead to increased revenues in the future, especially if the programs are successfully commercialized. Therefore, this news is likely to have a positive impact on Pfizer's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100